Experience

Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,300,000 shares of its common stock. The common stock is listed on the…

Davis Polk advised the underwriters in connection with an initial public offering of 16,100,000 shares of common stock of Revolution Medicines, Inc. at $17.00 per share (which includes the…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Revance Therapeutics, Inc. of $287.5 million aggregate principal amount of its 1.75% convertible senior…

Davis Polk advised the underwriters in connection with the $148.5 million public offering of ordinary shares by Theravance Biopharma, Inc. Theravance Biopharma’s ordinary shares…

Davis Polk advised the sole placing agent for the primary placement of an aggregate of 78,000,000 new shares in Innovent Biologics, Inc. for a total consideration of approximately HK$2.4…

Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 6,500,000 shares of common stock of Applied Genetic Technologies…

Davis Polk advised the underwriters in connection with a $75 million public offering of common stock by RAPT Therapeutics, Inc. RAPT Therapeutics’ common stock is listed on the …

Davis Polk advised the joint book-running managers in connection with the $180 million initial public offering of common stock of Beam Therapeutics Inc. The common stock is listed on the…

Davis Polk advised the joint book-running managers and representatives of the initial purchasers on a Rule 144A offering by Integra LifeSciences Holdings Corporation of $575 million…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the $281.75 million initial public offering by 1Life Healthcare, Inc…